Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071)

Xavier Montalban, Douglas L. Arnold, Amit Bar-Or, Anne H. Cross, Eva K. Havrdova, Olaf Stuve, Martin S. Weber, Heinz Wiendl, Jerry S. Wolinsky, Sana Syed, Matt Mandel, Emily C. Martin, Patrick Vermersch
First published April 14, 2020,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 94 no. 15 Supplement 4071
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 14, 2020.
Copyright & Usage: 
© 2020

Author Disclosures

    1. Xavier Montalban1,2,
    2. Douglas L. Arnold3,4,
    3. Amit Bar-Or5,
    4. Anne H. Cross6,
    5. Eva K. Havrdova7,
    6. Olaf Stuve8,
    7. Martin S. Weber9,
    8. Heinz Wiendl10,
    9. Jerry S. Wolinsky11,
    10. Sana Syed12,
    11. Matt Mandel12,
    12. Emily C. Martin12 and
    13. Patrick Vermersch13
  1. Xavier Montalban1,2,
  2. Douglas L. Arnold3,4,
  3. Amit Bar-Or5,
  4. Anne H. Cross6,
  5. Eva K. Havrdova7,
  6. Olaf Stuve8,
  7. Martin S. Weber9,
  8. Heinz Wiendl10,
  9. Jerry S. Wolinsky11,
  10. Sana Syed12,
  11. Matt Mandel12,
  12. Emily C. Martin12 and
  13. Patrick Vermersch13
  1. 1Vall d’Hebron University Hospital
  2. 2University of Toronto
  3. 3Montreal Neurological Institute, McGill Univ
  4. 4NeuroRx Research
  5. 5University of Pennsylvania
  6. 6Washington University School of Medicine
  7. 7Charles University
  8. 8UT Southwestern Medical Center
  9. 9Universitätsmedizin Göttingen
  10. 10University of Muenster
  11. 11McGovern Medical School, UTHealth
  12. 12EMD Serono Research and Development Institute, Inc.
  13. 13University of Lille

Article usage

Article usage: April 2020 to April 2022

AbstractFullPdfSource
Apr 20201700Highwire
May 20202800Highwire
Jun 20202600Highwire
Jul 20202000Highwire
Aug 20201500Highwire
Sep 20202400Highwire
Oct 20201200Highwire
Nov 20202400Highwire
Dec 20203500Highwire
Jan 20211600Highwire
Feb 20212200Highwire
Mar 20211000Highwire
Apr 20212900Highwire
May 20211600Highwire
Jun 2021700Highwire
Jul 20212300Highwire
Aug 2021800Highwire
Sep 2021900Highwire
Oct 20215000Highwire
Nov 20213100Highwire
Dec 20212500Highwire
Jan 20221900Highwire
Feb 20221200Highwire
Mar 20222900Highwire
Apr 20221600Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me